Below are Rx IP Update's most-read articles of 2023 (see also our 2023 Highlights in Canadian Life Sciences IP and Regulatory Law):
- Update on biosimilars in Canada – March 2023
- Supreme Court of Canada denies Apotex leave to appeal ONCA olanzapine Statutes of Monopolies decision
- Obviousness of Lilly's tadalafil (CIALIS) dosage form patent stands
- Lilly's Cialis patent claims extending to "physiologically acceptable salt" found invalid for overbreadth and insufficiency
- Federal Court dismisses Takeda's motion to consolidate two dexlansoprazole PMNOC actions against Apotex
- pCPA announces new three-year pricing initiative agreement for generic drugs with CGPA, appointment of Douglas Clark as its first CEO
- Federal Court refuses stay of impeachment action despite patentee's pending re-examination
- PM(NOC) Regulations: Six-year anniversary of major amendments
- PMPRB releases proposed amendment to Interim Guidance for comment
- Declaration of infringement does not preclude further NOA based on invalidity
Should you have any questions, please do not hesitate to contact a member of the Life Sciences Regulatory & Compliance Group or the Pharmaceutical Litigation Group.
The preceding is intended as a timely update on Canadian intellectual property and technology law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.
